Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes Academic Article uri icon

Overview

MeSH Major

  • Mutation
  • Myelodysplastic Syndromes
  • Polycomb Repressive Complex 2

abstract

  • Combining the LR-PSS and EZH2 mutation status identifies 29% of patients with lower-risk MDS with a worse-than-expected prognosis. These patients may benefit from earlier initiation of disease-modifying therapy.

publication date

  • September 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3438234

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.40.7379

PubMed ID

  • 22869879

Additional Document Info

start page

  • 3376

end page

  • 82

volume

  • 30

number

  • 27